One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Butterfly Network logo
Butterfly Network BFLY
$ 6.78 1.04%
report update icon

Quarterly report 2026-Q2
added 07-30-2026

Butterfly Network Income Statement 2025-2011 | BFLY

Brief overview of revenue and earnings at Butterfly Network

This overview is based on financial performance over the past five years. Revenue reported by Butterfly Network was 46.3 million dollars at the beginning of the period and 97.6 million dollars at the end. The total change was +111%, with a CAGR of approximately 16.1%. The pace indicates confident and sustained business growth.

The gross result shifted from −$61.2 million to $45.7 million, or +174.7%. The relationship between sales and direct costs improved over the period. Gross margin moved from −132.4% to 46.9%. Improving gross profitability strengthens the quality of revenue growth.

EBITDA was −$160 million at the beginning and −$79.7 million at the end of the period (+50.3%). Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin moved from −346.6% to −81.7%. The company improved its ability to convert sales into EBITDA.

The net financial result changed from −163 million dollars to −77.1 million dollars. Losses became smaller, but the business remains unprofitable.

Conclusion

The figures do not all move in the same direction. The strongest signals are net-income growth, a stronger gross margin and positive operating leverage. The most visible risks are a low EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.

Annual Income Statement Butterfly Network

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

946 M 766 M 253 M 388 M 1.16 B 120 M - - - - - - - - -

Shares

247 M 212 M 205 M 200 M 174 M 6.06 M - - - - - - - - -

Historical Prices

3.83 3.62 1.23 1.94 6.69 19.8 - - - - - - - - -

Net Income

-77.1 M -72.5 M -134 M -169 M -32.4 M -163 M - - - - - - - - -

Revenue

97.6 M 82.1 M 65.9 M 73.4 M 62.6 M 46.3 M - - - - - - - - -

Cost of Revenue

51.9 M 33.2 M 49 M 33.9 M 45.5 M 107 M 48.5 M - - - - - - - -

Gross Profit

45.7 M 48.8 M 16.9 M 39.5 M 17.1 M -61.2 M - - - - - - - - -

Operating Income

-86.4 M -74.4 M -146 M -193 M -193 M -162 M -102 M - - - - - - - -

Interest Expense

2.77 M -13 K -2 K 98 K 651 K 1.14 M -96 K - - - - - - - -

EBITDA

-79.7 M -65.5 M -137 M -187 M -191 M -160 M - - - - - - - - -

Operating Expenses

132 M 123 M 162 M 232 M 210 M 100 M - - - - - - - - -

General and Administrative Expenses

39.2 M 39.8 M 49.6 M 77.6 M 85.7 M 24.4 M - - - - - - - - -

All numbers in USD currency

Quarterly Income Statement Butterfly Network

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

262 M 257 M 252 M 248 M 235 M 213 M 212 M 209 M 207 M 205 M 203 M - 200 M 199 M 199 M - 196 M 192 M 106 M - 6.07 M 6.03 M 5.98 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-12.9 M -12.7 M -34 M -13.8 M -14 M -16.9 M -15.7 M -21.8 M -27.4 M -28.7 M -33.5 M - -54.7 M -35.8 M -44.5 M - -13.6 M -2.94 M -690 K - -92.2 M -23.2 M -24.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

32.6 M 26.5 M 21.5 M 23.4 M 21.2 M 20.6 M 21.5 M 17.7 M 15.4 M 18.5 M 15.5 M - 19.6 M 19.2 M 15.6 M - 14.6 M 16.5 M 12.4 M - 10.1 M 11.8 M 8.67 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

9.32 M 8.24 M 25.2 M 8.49 M 7.84 M 8.33 M 8.9 M 7.38 M 6.04 M 7.56 M 6.39 M - 8.63 M 8.64 M 7.23 M - 19.7 M 8.29 M 6.03 M - 79.4 M 11.6 M 9.51 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

23.3 M 18.3 M -3.76 M 14.9 M 13.4 M 12.2 M 12.6 M 10.3 M 9.38 M 10.9 M 9.09 M - 11 M 10.6 M 8.34 M - -5.12 M 8.22 M 6.42 M - -69.3 M 165 K -836 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-13.7 M -13.9 M -35.1 M -16.1 M -18.5 M -17.2 M -17.2 M -22.6 M -32.6 M -31.3 M -35 M - -46 M -48.5 M -49.5 M - -57 M -36.7 M -53.7 M - -91.8 M -23.1 M -24.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

-43 K -124 K -86 K 531 K 2.38 M 717 K -59 K -141 K -217 K -60 K 17 K - 2 K -388 K -100 K - 645 K 7 K 638 K - 300 K 113 K 5 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-13.7 M -13.9 M -35.1 M -16.1 M -18.5 M - - - - - -32.9 M - -42 M -48.5 M -48.7 M - -55.6 M -36.7 M -53.3 M - -90.9 M -22.5 M -24.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

37 M 32.2 M 31.4 M 31 M 31.8 M 29.5 M 29.8 M 32.9 M 41.9 M 42.2 M 44.1 M - 57 M 59 M 57.9 M - 51.9 M 44.9 M 60.2 M - 22.6 M 23.2 M 23.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

11.4 M 10.8 M 9.29 M 9.13 M 9.6 M 9.35 M 10.1 M 10.4 M 11.6 M 14.7 M 11 M - 16.6 M 18.7 M 18.8 M - 16 M 17.3 M 34.6 M - 5.07 M 5.34 M 5.24 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Butterfly Network (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Orthofix Medical Orthofix Medical
OFIX
$ 9.7 -1.12 % $ 384 M curacaoCuracao
TransMedics Group TransMedics Group
TMDX
$ 71.03 0.41 % $ 2.41 B usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 5.05 1.78 % $ 3.4 M usaUSA
AxoGen AxoGen
AXGN
$ 38.31 0.64 % $ 1.76 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Venus Concept Venus Concept
VERO
- - $ 726 K usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Viveve Medical Viveve Medical
VIVE
- -15.35 % $ 1.71 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
ViewRay ViewRay
VRAY
- 1.54 % $ 468 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 47.96 -2.48 % $ 1.49 B usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 9.05 -1.04 % $ 256 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA
Delcath Systems Delcath Systems
DCTH
$ 14.66 1.66 % $ 525 M usaUSA
SeaSpine Holdings Corporation SeaSpine Holdings Corporation
SPNE
- 0.28 % $ 270 M usaUSA
Zynex Zynex
ZYXI
- - $ 21.1 M usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Globus Medical Globus Medical
GMED
$ 81.12 -0.36 % $ 11 B usaUSA
Nemaura Medical Nemaura Medical
NMRD
- -17.8 % $ 2.74 M britainBritain
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 12.07 1.34 % $ 925 M usaUSA
InMode Ltd. InMode Ltd.
INMD
$ 13.77 -1.43 % $ 890 M israelIsrael
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 2.41 1.69 % $ 99 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.12 -4.69 % $ 14.7 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 85.76 -0.12 % $ 1.09 B usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 126.54 -0.01 % $ 4.4 B usaUSA
Inogen Inogen
INGN
$ 7.05 -0.77 % $ 188 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 57.98 0.68 % $ 8.8 B usaUSA